BridgeBio Oncology Therapeutics, Inc. Operating Expenses
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Operating Expenses of $60.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $60.19M, a 100.00% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $46.18M, a 99.59% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $43.41M, a 98.40% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $49.18M, a 150.11% increase year-over-year.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.19M 10-Q · filed 2026-08-11 | $106.37M 10-Q · filed 2026-08-11 | $149.77M derived: sum of 3 quarters · filed 2026-08-11 | $198.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $46.18M 10-Q · filed 2026-05-12 | $89.59M derived: sum of 2 quarters · filed 2026-05-12 | $138.77M derived: sum of 3 quarters · filed 2026-05-12 | $168.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $43.41M 8-K · filed 2026-03-05 | $92.59M derived: sum of 2 quarters · filed 2026-03-05 | $122.68M derived: sum of 3 quarters · filed 2026-08-11 | $145.82M POS AM · filed 2026-04-30 |
| 2025-09-30 | $49.18M 10-Q · filed 2025-11-12 | $79.27M derived: sum of 2 quarters · filed 2026-08-11 | $102.41M 10-Q · filed 2025-11-12 | $124.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $30.09M 10-Q · filed 2026-08-11 | $53.23M 10-Q · filed 2026-08-11 | $75.11M derived: sum of 3 quarters · filed 2026-08-11 | $94.77M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $23.14M 10-Q · filed 2026-05-12 | $45.02M derived: sum of 2 quarters · filed 2026-05-12 | $64.68M derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $21.88M 8-K · filed 2026-03-05 | $41.54M derived: sum of 2 quarters · filed 2026-03-05 | $80.86M POS AM · filed 2026-04-30 | |
| 2024-09-30 | $19.66M 10-Q · filed 2025-11-12 | $58.98M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |